Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $785M (up 11.7% year over year) with net income of $2M.
Q3 2025 key financials · XBRL
- Revenue
- $785M
- +11.7% YoY · +8.3% QoQ
- Net income
- $2M
- +1618.6% YoY · −89.4% QoQ
- Operating margin
- 9.0%
- Gross margin
- 34.9%
- EPS (diluted)
- $0.00
- −100.0% QoQ
Source: XBRL data from the Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 10-Q on SEC EDGAR. USD.
Amneal Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin figures provided in MD&A section
- No segment or product line performance details mentioned
- $24.2 million deposited toward opioids litigation settlement in July 2025, pending definitive agreement
- Tax receivable agreement liability $141.4 million as of Sept 30, 2025 with $3.0 million paid year-to-date
Risk Factors
- New tax distribution risk due to increased cash distributions to AvKARE Sellers: $38.8M in nine months ended 9/30/25 vs $14.4M prior year
- Material debt refinancing changes reducing financing cash outflows by $129.2M to $21.4M nine months ended 9/30/25
- Foreign exchange exposure risk from cash holdings in non-U.S. banks affecting market risk on cash and equivalents
- Increased capital expenditures and deposits raising investing cash use by $19.9M to $66.8M nine months ended 9/30/25
- Working capital impacts offsetting cash earnings growth, leading to reduced net operating cash flow excluding litigation settlement
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amneal Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.